Treatable inherited rare movement disorders
Corresponding Author
H. A. Jinnah MD, PhD
Departments of Neurology, Human Genetics and Pediatrics, Emory University, Atlanta, Georgia, USA
Corresponding author: Dr. Emilia M. Gatto, Department of Neurology, Affiliated University of Buenos Aires, Buenos Aires, Argentina; [email protected]Search for more papers by this authorAlberto Albanese MD
Department of Neurology, Humanitas Research Hospital, Rozzano, Italy
Catholic University, Milan, Italy
Search for more papers by this authorKailash P. Bhatia MD
Sobell Department of Motor Neuroscience and Movement Disorders, University College London Institute of Neurology, London, United Kingdom
Search for more papers by this authorFrancisco Cardoso MD
Department of Internal Medicine, Movement Disorders Clinic, Neurology Service, UFMG, Belo Horizonte, MG, Brazil
Search for more papers by this authorGustavo Da Prat MD
Department of Neurology, Affiliated University of Buenos Aires, Buenos Aires, Argentina
University DelSalvadore, Buenos Aires, Argentina
Search for more papers by this authorTom J. de Koning MD, PhD
Department of Genetics, Pediatrics and Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Search for more papers by this authorAlberto J. Espay MD
James J. and Joan A. Gardner Center for Parkinson's disease and Movement Disorders, University of Cincinnati, Ohio, USA
Search for more papers by this authorVictor Fung PhD, FRACP
Movement Disorders Unit, Department of Neurology, Westmead Hospital & Sydney Medical School, University of Sydney, Sydney, Australia
Search for more papers by this authorPedro J. Garcia-Ruiz MD
Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
Search for more papers by this authorOscar Gershanik MD, PhD
Institute of Neuroscience, Favaloro Foundation University Hospital, Buenos Aires, Argentina
Search for more papers by this authorJoseph Jankovic MD
Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA
Search for more papers by this authorRyuji Kaji MD, PhD
Department of Neurology, Tokushima University Graduate School of Medicine, Tokushima, Japan
Search for more papers by this authorKatya Kotschet MD
Clinical Neurosciences, St. Vincent's Health, Melbourne, Australia
Search for more papers by this authorConnie Marras MD, PhD
The Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, University of Toronto, Toronto, Canada
Search for more papers by this authorJanis M. Miyasaki MD, MEd
Division of Neurology, University of Alberta, Edmonton, Canada
Search for more papers by this authorFrancesca Morgante MD
Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
Search for more papers by this authorAlexander Munchau MD
Department of Pediatric and Adult Movement Disorders and Neuropsychiatry, Institute of Neurogenetics, University of Lübeck, Lübeck, Germany
Search for more papers by this authorPramod Kumar Pal MBBS, MD, DM
Department of Neurology, National Institute of Mental Health & Neuroscience, Bangalore, India
Search for more papers by this authorMaria C. Rodriguez Oroz MD
University Hospital Donostia, Madrid, Spain
BioDonostia Research Institute, Basque Center on Cognition, Brain and Language, San Sebastian, Madrid, Spain
Ikerbasque, Basque Foundation for Science, Bilbao, Spain
Network Center for Biomedical Research in Neurodegenerative Diseases, Madrid, Spain
Search for more papers by this authorMayela Rodríguez-Violante MD
Movement Disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
Search for more papers by this authorLudger Schöls MD
Department of Neurology and Hertie Institute for Clinical Brain Research, University of Tubingen, Tubingen, Germany
German Center for Neurodegenerative Diseases, Tubingen, Germany
Search for more papers by this authorMaria Stamelou MD
Neurology Clinic, Philipps University Marburg, Marburg, Germany
Parkinson's Disease and Other Movement Disorders Department, HYGEIA Hospital, Athens, Greece
Search for more papers by this authorMarina Tijssen MD, PhD
Department of Neurology, University Medical Center Groningen, University of Groningen, The Netherlands
Search for more papers by this authorClaudia Uribe Roca MD
Department of Neurology, British Hospital of Buenos Aires, Buenos Aires, Argentina
Search for more papers by this authorAndres de la Cerda MD
Clinica Davila, CINSAN, Universidad de los Andes, Santiago, Chile
Search for more papers by this authorCorresponding Author
Emilia M. Gatto MD
Department of Neurology, Affiliated University of Buenos Aires and University DelSalvadore, Buenos Aires, Argentina
Corresponding author: Dr. Emilia M. Gatto, Department of Neurology, Affiliated University of Buenos Aires, Buenos Aires, Argentina; [email protected]Search for more papers by this authorfor the International Parkinson's Disease Movement Disorders Society Task Force on Rare Movement Disorders
Search for more papers by this authorCorresponding Author
H. A. Jinnah MD, PhD
Departments of Neurology, Human Genetics and Pediatrics, Emory University, Atlanta, Georgia, USA
Corresponding author: Dr. Emilia M. Gatto, Department of Neurology, Affiliated University of Buenos Aires, Buenos Aires, Argentina; [email protected]Search for more papers by this authorAlberto Albanese MD
Department of Neurology, Humanitas Research Hospital, Rozzano, Italy
Catholic University, Milan, Italy
Search for more papers by this authorKailash P. Bhatia MD
Sobell Department of Motor Neuroscience and Movement Disorders, University College London Institute of Neurology, London, United Kingdom
Search for more papers by this authorFrancisco Cardoso MD
Department of Internal Medicine, Movement Disorders Clinic, Neurology Service, UFMG, Belo Horizonte, MG, Brazil
Search for more papers by this authorGustavo Da Prat MD
Department of Neurology, Affiliated University of Buenos Aires, Buenos Aires, Argentina
University DelSalvadore, Buenos Aires, Argentina
Search for more papers by this authorTom J. de Koning MD, PhD
Department of Genetics, Pediatrics and Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Search for more papers by this authorAlberto J. Espay MD
James J. and Joan A. Gardner Center for Parkinson's disease and Movement Disorders, University of Cincinnati, Ohio, USA
Search for more papers by this authorVictor Fung PhD, FRACP
Movement Disorders Unit, Department of Neurology, Westmead Hospital & Sydney Medical School, University of Sydney, Sydney, Australia
Search for more papers by this authorPedro J. Garcia-Ruiz MD
Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
Search for more papers by this authorOscar Gershanik MD, PhD
Institute of Neuroscience, Favaloro Foundation University Hospital, Buenos Aires, Argentina
Search for more papers by this authorJoseph Jankovic MD
Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA
Search for more papers by this authorRyuji Kaji MD, PhD
Department of Neurology, Tokushima University Graduate School of Medicine, Tokushima, Japan
Search for more papers by this authorKatya Kotschet MD
Clinical Neurosciences, St. Vincent's Health, Melbourne, Australia
Search for more papers by this authorConnie Marras MD, PhD
The Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, University of Toronto, Toronto, Canada
Search for more papers by this authorJanis M. Miyasaki MD, MEd
Division of Neurology, University of Alberta, Edmonton, Canada
Search for more papers by this authorFrancesca Morgante MD
Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
Search for more papers by this authorAlexander Munchau MD
Department of Pediatric and Adult Movement Disorders and Neuropsychiatry, Institute of Neurogenetics, University of Lübeck, Lübeck, Germany
Search for more papers by this authorPramod Kumar Pal MBBS, MD, DM
Department of Neurology, National Institute of Mental Health & Neuroscience, Bangalore, India
Search for more papers by this authorMaria C. Rodriguez Oroz MD
University Hospital Donostia, Madrid, Spain
BioDonostia Research Institute, Basque Center on Cognition, Brain and Language, San Sebastian, Madrid, Spain
Ikerbasque, Basque Foundation for Science, Bilbao, Spain
Network Center for Biomedical Research in Neurodegenerative Diseases, Madrid, Spain
Search for more papers by this authorMayela Rodríguez-Violante MD
Movement Disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico
Search for more papers by this authorLudger Schöls MD
Department of Neurology and Hertie Institute for Clinical Brain Research, University of Tubingen, Tubingen, Germany
German Center for Neurodegenerative Diseases, Tubingen, Germany
Search for more papers by this authorMaria Stamelou MD
Neurology Clinic, Philipps University Marburg, Marburg, Germany
Parkinson's Disease and Other Movement Disorders Department, HYGEIA Hospital, Athens, Greece
Search for more papers by this authorMarina Tijssen MD, PhD
Department of Neurology, University Medical Center Groningen, University of Groningen, The Netherlands
Search for more papers by this authorClaudia Uribe Roca MD
Department of Neurology, British Hospital of Buenos Aires, Buenos Aires, Argentina
Search for more papers by this authorAndres de la Cerda MD
Clinica Davila, CINSAN, Universidad de los Andes, Santiago, Chile
Search for more papers by this authorCorresponding Author
Emilia M. Gatto MD
Department of Neurology, Affiliated University of Buenos Aires and University DelSalvadore, Buenos Aires, Argentina
Corresponding author: Dr. Emilia M. Gatto, Department of Neurology, Affiliated University of Buenos Aires, Buenos Aires, Argentina; [email protected]Search for more papers by this authorfor the International Parkinson's Disease Movement Disorders Society Task Force on Rare Movement Disorders
Search for more papers by this authorRelevant conflicts of interests/financial disclosures: Nothing to report.
ABSTRACT
There are many rare movement disorders, and new ones are described every year. Because they are not well recognized, they often go undiagnosed for long periods of time. However, early diagnosis is becoming increasingly important. Rapid advances in our understanding of the biological mechanisms responsible for many rare disorders have enabled the development of specific treatments for some of them. Well-known historical examples include Wilson disease and dopa-responsive dystonia, for which specific and highly effective treatments have life-altering effects. In recent years, similarly specific and effective treatments have been developed for more than 30 rare inherited movement disorders. These treatments include specific medications, dietary changes, avoidance or management of certain triggers, enzyme replacement therapy, and others. This list of treatable rare movement disorders is likely to grow during the next few years because a number of additional promising treatments are actively being developed or evaluated in clinical trials. © 2017 International Parkinson and Movement Disorder Society
References
- 1Richter T, Nestler-Parr S, Babela R, et al. Rare disease terminology and definitions—a systematic global review: report of the ISPOR rare disease special interest group. Value Health 2015; 18: 906-914.
- 2Rodwell C, Ayme S. Rare disease policies to improve care for patients in Europe. Biochim Biophys Acta 2015; 1852: 2329-2335.
- 3Bellgard M, Beroud C, Parkinson K, et al. Dispelling myths about rare disease registry system development. Source Code Biol Med 2013; 8: 21.
- 4Gammie T, Lu CY, Babar ZU. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS One 2015; 10: e0140002.
- 5Gauthier J, Rouleau GA. De novo mutations in neurological and psychiatric disorders: effects, diagnosis and prevention. Genome Med 2012; 4: 71.
10.1186/gm372 Google Scholar
- 6Field M, Boat T. Institute of Medicine (US) Commitee on Accelerating Rare Diseases Research and Development. Rare diseases and orphan products: accelerating research and development. The National Academies Collection: National Academies Press 2010.
- 7Ayme S, Bellet B, Rath A. Rare diseases in ICD11: making rare diseases visible in health information systems through appropriate coding. Orphanet J Rare Dis 2015; 10: 35.
- 8Gerss JW, Kopcke W. Clinical trials and rare diseases. Adv Exp Med Biol 2010; 686: 173-190.
- 9Gagne JJ, Thompson L, O'Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ 2014; 349: g6802.
- 10Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis 2014; 9: 170.
- 11Killoran A, Biglan KM. Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches? Mov Disord 2014; 29: 1404-1413.
- 12Gray RGF, Preece MA, Green SH, Whitehouse W, Winer J, Green A. Inborn errors of metabolism as a cause of neurological disease in adults : approach to investigation. J Neurol Neurosurg Psychiatry 2000; 69: 12-May.
- 13Sedel F, Lyon-Caen O, Saudubray JM. Therapy insight: inborn errors of metabolism in adult neurology— a clinical approach focusssed on treatable diseases. Nat Clin Pract Neurol 2007; 3: 279-290.
- 14Sedel F, Saudubray JM, Roze E, Agid Y, Vidailhet M. Movement disorders and inborn errors of metabolism in adults: a diagnostic approach. J Inherit Metab Dis 2008; 31: 308-318.
- 15Murphy E. Pregnancy in women with inherited metabolic disease. Obstet Med 2015; 8: 61-67.
- 16Langendonk JG, Roos JC, Angus L, et al. A series of pregnancies in women with inherited metabolic disease. J Inherit Metab Dis 2012; 35: 419-424.
- 17Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. Lancet Neurol 2015; 14: 103-113.
- 18Tuschl K, Meyer E, Valdivia LE, et al. Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism-dystonia. Nat Commun 2016; 7: 11601.
- 19Nie S, Chen G, Cao X, Zhang Y. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis 2014; 9: 179.
- 20Santos-Lozano A, Villamandos Garcia D, Sanchis-Gomar F, et al. Niemann-Pick disease treatment: a systematic review of clinical trials. Ann Transl Med 2015; 3: 360.
- 21Vockley J, Andersson HC, Antshel KM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med 2014; 16: 188-200.
- 22Morris AA, Kozich V, Santra S, et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis 2017; 40: 49-74.
- 23Simon E, Flaschker N, Schadewaldt P, Langenbeck U, Wendel U. Variant maple syrup urine disease (MSUD)—the entire spectrum. J Inherit Metab Dis 2006; 29: 716-724.
- 24Zolotov D, Wagner S, Kalb K, Bunia J, Heibges A, Klingel R. Long-term strategies for the treatment of Refsum's disease using therapeutic apheresis. J Clin Apher 2012; 27: 99-105.
- 25Baldwin EJ, Gibberd FB, Harley C, Sidey MC, Feher MD, Wierzbicki AS. The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease. J Neurol Neurosurg Psychiatry 2010; 81: 954-957.
- 26Lee J, Hegele RA. Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. J Inherit Metab Dis 2014; 37: 333-339.
- 27Weber YG, Kamm C, Suls A, et al. Paroxysmal choreoathetosis/spasticity (DYT9) is caused by a GLUT1 defect. Neurology 2011; 77: 959-964.
- 28Kass HR, Winesett SP, Bessone SK, Turner Z, Kossoff EH. Use of dietary therapies amongst patients with GLUT1 deficiency syndrome. Seizure 2016; 35: 83-87.
- 29Sperl W, Fleuren L, Freisinger P, et al. The spectrum of pyruvate oxidation defects in the diagnosis of mitochondrial disorders. J Inherit Metab Dis 2015; 38: 391-403.
- 30Sofou K, Dahlin M, Hallbook T, Lindefeldt M, Viggedal G, Darin N. Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes. J Inherit Metab Dis 2017; 40: 237-245.
- 31Castiglioni C, Verrigni D, Okuma C, et al. Pyruvate dehydrogenase deficiency presenting as isolated paroxysmal exercise induced dystonia successfully reversed with thiamine supplementation. Case report and mini-review. Eur J Paediatr Neurol 2015; 19: 497-503.
- 32Wolf B. Successful outcomes of older adolescents and adults with profound biotinidase deficiency identified by newborn screening. Genet Med 2017; 19: 396-402.
- 33Tabarki B, Alfadhel M, AlShahwan S, Hundallah K, AlShafi S, AlHashem A. Treatment of biotin-responsive basal ganglia disease: open comparative study between the combination of biotin plus thiamine versus thiamine alone. Eur J Paediatr Neurol 2015; 19: 547-552.
- 34Emmanuele V, López LC, Berardo A, et al. Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch Neurol 2012; 69: 978-983.
- 35Stockler-Ipsiroglu S, van Karnebeek CD. Cerebral creatine deficiencies: a group of treatable intellectual developmental disorders. Semin Neurol 2014; 34: 350-356.
- 36Atwal PS, Scaglia F. Molybdenum cofactor deficiency. Mol Genet Metab 2016; 117: 1-4.
- 37Baumgartner MR. Vitamin-responsive disorders: cobalamin, folate, biotin, vitamins B1 and E. Handb Clin Neurol 2013; 113: 1799-1810.
- 38Schuelke M. Ataxia with vitamin e deficiency. In: RA Pagon, MP Adam, HH Ardinger, et al., eds. GeneReviews. University of Washington, Seattle, WA. 1993.
- 39Brun L, Ngu LH, Keng WT, et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology 2010; 75: 64-71.
- 40Wassenberg T, Molero-Luis M, Jeltsch K, et al. Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. Orphanet J Rare Dis 2017; 12: 12.
- 41Lossos A, Teltsh O, Milman T, et al. Severe methylenetetrahydrofolate reductase deficiency: clinical clues to a potentially treatable cause of adult-onset hereditary spastic paraplegia. JAMA Neurology 2014; 71: 901-904.
- 42Heringer J, Boy SP, Ensenauer R, et al. Use of guidelines improves the neurological outcome in glutaric aciduria type I. Ann Neurol 2010; 68: 743-752.
- 43Kolker S, Christensen E, Leonard JV, et al. Diagnosis and management of glutaric aciduria type I—revised recommendations. J Inherit Metab Dis 2011; 34: 677-694.
- 44Baumgartner MR, Horster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis 2014; 9: 130.
- 45Heinzen EL, Arzimanoglou A, Brashear A, et al. Distinct neurological disorders with ATP1A3 mutations. Lancet Neurol 2014; 13: 503-514.
- 46Kurian MA, Gissen P, Smith M, Heales S Jr, Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol 2011; 10: 721-733.
- 47Willemsen MA, Verbeek MM, Kamsteeg EJ, et al. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 2010; 133: 1810-1822.
- 48Friedman J, Roze E, Abdenur JE, et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 2012; 71: 520-530.
- 49Ye J, Yang Y, Yu W, et al. Demographics, diagnosis and treatment of 256 patients with tetrahydrobiopterin deficiency in mainland China: results of a retrospective, multicentre study. J Inherit Metab Dis 2013; 36: 893-901.
- 50Mochel F, Hainque E, Gras D, et al. Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. J Neurol Neurosurg Psychiatry 2016; 87: 550-553.
- 51Ilg W, Bastian A, Boesch S, et al. Consensus paper: management of degenerative cerebellar disorders. The Cerebellum 2014; 13: 248-268.
- 52Strzelczyk A, Burk K, Oertel WH. Treatment of paroxysmal dyskinesias. Expert Opin Pharmacother 2011; 12: 63-72.
10.1517/14656566.2010.513971 Google Scholar
- 53Kollensperger M, Geser F, Seppi K, et al. Red flags for multiple system atrophy. Mov Disord 2008; 23: 1093-1099.
- 54Martino D, Stamelou M, Bhatia KP. The differential diagnosis of Huntington's disease-like syndromes: ‘red flags’ for the clinician. J Neurol Neurosurg Psychiatry 2013; 84: 650-656.
- 55Stamelou M, Lai SC, Aggarwal A, et al. Dystonic opisthotonus: a “red flag” for neurodegeneration with brain iron accumulation syndromes? Mov Disord 2013; 28: 1325-1329.
- 56Abdo WF, van de Warrenburg BP, Burn DJ, Quinn NP, Bloem BR. The clinical approach to movement disorders. Nat Rev Neurol 2010; 6: 29-37.
- 57Fung VS, Jinnah HA, Bhatia K, Vidailhet M. Assessment of the patient with dystonia: an update on dystonia syndromes. Mov Disord 2013; 28: 889-898.
- 58Jinnah HA, Factor S. Diagnosis and treatment of dystonia. In: J Jankovic, ed. Neurologic 2015; 33: 77-100.
- 59Charlesworth G, Bhatia KP, Wood NW. The genetics of dystonia: new twists in an old tale. Brain 2013; 136: 2017-2037.
- 60Schneider SA, Bhatia KP. Secondary dystonia—clinical clues and syndromic associations. Eur J Neurol 2010; 17(suppl 1): 52-57.
- 61Camargos S, Cardoso F. New algorithm for the diagnosis of hereditary dystonia. Arq Neuropsiquiatr 2012; 70: 715-717.
10.1590/S0004-282X2012000900013 Google Scholar
- 62van Egmond ME, Kuiper A, Eggink H, et al. Dystonia in children and adolescents: a systematic review and a new diagnostic algorithm. J Neurol Neurosurg Psychiatry 2014; 86: 774-781.
- 63Garcia-Cazorla A, Wolf NI, Serrano M, et al. Inborn errors of metabolism and motor disturbances in children. J Inherit Metab Dis 2009; 32: 618-629.
- 64Martikainen MH, Ng YS, Gorman GS, et al. Clinical, genetic, and radiological features of extrapyramidal movement disorders in mitochondrial disease. JAMA Neurol 2016; 73: 668-674.
- 65Charlesworth G, Mohire MD, Schneider SA, Stamelou M, Wood NW, Bhatia KP. Ataxia telangiectasia presenting as dopa-responsive cervical dystonia. Neurology 2013; 81: 1148-1151.
- 66Meneret A, Ahmar-Beaugendre Y, Rieunier G, et al. The pleiotropic movement disorders phenotype of adult ataxia-telangiectasia. Neurology 2014; 83: 1087-1095.
- 67Saunders-Pullman R, Raymond D, Stoessl AJ, et al. Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites. Neurology 2012; 78: 649-657.
- 68Verhagen MM, Abdo WF, Willemsen MA, et al. Clinical spectrum of ataxia-telangiectasia in adulthood. Neurology 2009; 73: 430-437.
- 69Tonduti D, Chiapparini L, Moroni I, et al. Neurological disorders associated with striatal lesions: Classification and diagnostic approach. Curr Neurol Neurosci Rep 2016; 16: 54.
- 70Finelli PF, DiMario FJ Jr. Diagnostic approach in patients with symmetric imaging lesions of the deep gray nuclei. Neurologist 2003; 9: 250-261.
- 71Kim JS, Choi IS, Lee MC. Reversible parkinsonism and dystonia following probable mycoplasma pneumoniae infection. Mov Disord 1995; 10: 510-512.
- 72Cunningham MW, Cox CJ. Autoimmunity against dopamine receptors in neuropsychiatric and movement disorders: a review of Sydenham chorea and beyond. Acta Physiol (Oxf) 2016; 216: 90-100.
- 73Shashi V, McConkie-Rosell A, Rosell B, et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. Genet Med 2014; 16: 176-182.
- 74Xue Y, Ankala A, Wilcox WR, Hegde MR. Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing. Genet Med 2014; 17: 441-451.
- 75Foley AR, Donkervoort S, Bonnemann CG. Next-generation sequencing still needs our generation's clinicians. Neurol Genet 2015; 1: e13.
- 76Olgiati S, Quadri M, Bonifati V. Genetics of movement disorders in the next-generation sequencing era. Mov Disord 2016; 31: 458-470.
- 77Lill CM, Mashychev A, Hartmann C, et al. Launching the movement disorders society genetic mutation database (MDSGene). Mov Disord 2016; 31: 607-609.
- 78Shemesh E, Deroma L, Bembi B, et al. Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database Syst Rev 2015: CD010324.
- 79Monestime G, Borger DK, Kim J, et al. Varied autopsy findings in five treated patients with Gaucher disease and parkinsonism include the absence of Gaucher cells. Mol Genet Metab 2016; 118: 55-59.
10.1016/j.ymgme.2016.02.008 Google Scholar
- 80Barkhuizen M, Anderson DG, Grobler AF. Advances in GBA-associated Parkinson's disease—pathology, presentation and therapies. Neurochem Int 2016; 93: 6-25.
- 81Sturm E, Piersma FE, Tanner MS, Socha P, Roberts EA, Shneider BL. Controversies and variation in diagnosing and treating children with Wilson disease: results of an international survey. J Pediatr Gastroenterol Nutr 2016; 63: 82-87.
- 82Griggs RC, Batshaw M, Dunkle M, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009; 96: 20-26.
- 83Mitsumoto J, Dorsey ER, Beck CA, Kieburtz K, Griggs RC. Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol 2009; 66: 184-190.
- 84Leen WG, Mewasingh L, Verbeek MM, Kamsteeg EJ, van de Warrenburg BP, Willemsen MA. Movement disorders in GLUT1 deficiency syndrome respond to the modified Atkins diet. Mov Disord 2013; 28: 1439-1442.
- 85Carecchio M, Schneider SA, Chan H, et al. Movement disorders in adult surviving patients with maple syrup urine disease. Mov Disord 2011; 26: 1324-1328.
- 86Wijemanne S, Jankovic J. Dopa-responsive dystonia—clinical and genetic heterogeneity. Nat Rev Neurol 2015; 11: 414-424.
- 87Molero-Luis M, Serrano M, O'Callaghan MM, et al. Clinical, etiological and therapeutic aspects of cerebral folate deficiency. Expert Rev Neurother 2015; 15: 793-802.